A novel compound, SYHA1813, inhibits malignant meningioma growth directly by boosting p53 pathway activation and impairing DNA repair
This study unveiled a novel antitumor mechanism of SYHA1813, showing its ability to directly target and kill meningioma cells <i>in vitro</i> and <i>in vivo</i>. Our findings highlighted the promising potential of SYHA1813 as a therapeutic agent for treating malignant meningiomas.
Authors
- Jiachen Wang (ORCID: https://orcid.org/0000-0002-5070-7309)
- Mengqian Huang (ORCID: https://orcid.org/0000-0002-6009-0779)
- Feng Chen (ORCID: https://orcid.org/0000-0002-4184-9719)
- Wenbin Li (ORCID: https://orcid.org/0000-0003-3096-4831)
- Rong Zhang (ORCID: https://orcid.org/0000-0001-5233-2718)
- Shenglan Li (ORCID: https://orcid.org/0009-0009-3685-0334)
- Xin Yang (ORCID: https://orcid.org/0000-0002-5217-0795)
- Yanjie Lan (ORCID: https://orcid.org/0009-0009-8502-4813)
- Can Wang (ORCID: https://orcid.org/0009-0006-9851-2902)
Institutions
- Capital Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-02-20
- DOI
- https://doi.org/10.3389/fonc.2025.1522249
- Citations
- 2
- Primary Topic
- Meningioma and schwannoma management
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- National Natural Science Foundation of China